ALNY vs HRMY
ALNY: Alnylam is a pioneer in RNA interference (RNAi) therapeutics, using gene-silencing technology to treat rare genetic diseases and cardiovascular conditions. HRMY: Harmony Biosciences is a neuroscience-focused biopharmaceutical company commercializing WAKIX (pitolisant), the first-in-class non-controlled H3 receptor antagonist for narcolepsy, with an expanding pipeline in rare epilepsy and sleep disorders.
Side-by-side fundamentals
| Metric | ALNY | HRMY | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $278.40 | $36.01 | |
| Market cap as of 2026-07-31 | $36.9B | $2.1B | |
| P/E as of 2026-07-31 | 50.14 | 14.26 | HRMY lower |
| PEG as of 2026-07-31 | 1.11 | 0.20 | HRMY lower |
| Net margin as of 2026-07-31 | +13.5% | +16.2% | HRMY higher |
| Gross margin as of 2026-07-31 | +80.8% | +76.5% | ALNY higher |
| Operating margin as of 2026-07-31 | +16.6% | +21.1% | HRMY higher |
| ROE as of 2026-07-31 | +98.3% | +17.2% | ALNY higher |
| ROA as of 2026-07-31 | +11.8% | +12.0% | HRMY higher |
| Debt / equity as of 2026-07-31 | 2.52 | 0.17 | HRMY lower |
| Revenue growth (YoY) as of 2026-07-31 | +82.6% | +20.7% | ALNY higher |
| Revenue CAGR (3y) SEC XBRL | +53.0% | +25.6% | ALNY higher |
| Beta as of 2026-07-31 | 0.28 | 0.91 | |
| 1-year return as of 2026-07-27 close | -15.3% | -4.0% | HRMY higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.